A Phase 2b randomised, double blind, placebo-controlled trial of trimetazidine therapy in patients with non-obstructive hypertrophic cardiomyopathy.

Trial Profile

A Phase 2b randomised, double blind, placebo-controlled trial of trimetazidine therapy in patients with non-obstructive hypertrophic cardiomyopathy.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Trimetazidine (Primary)
  • Indications Hypertrophic cardiomyopathy
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Jul 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
    • 18 Jul 2015 Status changed from recruiting to discontinued as per European Clinical Trials Database record.
    • 16 Oct 2014 Accrual to date is 60% according to United Kingdom Clinical Research Network record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top